Phreesia, Inc.
NYSE:PHRMedical - Healthcare Information Services
+$0.08 today
- Market cap
- $760.99M
- Beta
- 0.88
- P/E (TTM)
- 62.6
- EPS (TTM)
- $0.15
Volume 0.86M
Average 1.97M
PHR EBITDA Margin
EBITDA as a percentage of revenue.
Phreesia, Inc.NYSE: PHR
EBITDA Margin · Q1 FY2027 · quarter ended Apr 2026
EBITDA Margin widens to 13.1%
EBITDA Margin was 13.1% in Q1 FY2027, up 9.5 pp from a year earlier. On a trailing-twelve-month basis it was 8.6%, up 10.7 pp year over year. Over 3 fiscal years it widened by 57.9 pp.
Context
- EBITDA Margin widened in 3 of the last 3 fiscal years.
- FY2026 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 13 analysts of 11.7% for the fiscal year ending Jan 2027, up from 6.1% in FY2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterApr 2026
- 13.1%+9.0 pp QoQ
- Last fiscal yearJan 2026
- 6.1%+12.2 pp YoY
- LTMApr 2026
- 8.6%+10.7 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +9.5 pp | +9.0 pp | -0.4 pp |
| 1 year | +12.2 pp | +5.6 pp | -6.7 pp |
| 3 years | +57.9 pp | +10.8 pp | -47.1 pp |
| 5 years | +13.1 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2026
- 6.1%
- Year-over-year change
- +12.2pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2026 | 2026-01-31 | 6.1% | +12.2pp |
| FY2025 | 2025-01-31 | -6.1% | +22.8pp |
| FY2024 | 2024-01-31 | -28.9% | +22.9pp |
| FY2023 | 2023-01-31 | -51.8% | -8.5pp |
| FY2022 | 2022-01-31 | -43.3% | — |
EBITDA Margin vs competitors
How PHR compares with its peers on the latest reported figures
- PHR's LTM Apr 2026 EBITDA Margin of 8.6% is the 4th highest of the 11 companies compared; the peer median is -1.9%.
- Its year-over-year change of +10.7 pp is the 5th highest of 11, against a peer median of +0.8 pp.
- Over three fiscal years its change of +57.9 pp compares with a peer median of +14.6 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 22.0% | +0.5 pp | +14.6 pp | |
| LTM Aug 2026 | 11.9% | +111.0 pp | +3.8 pp | |
| LTM Mar 2026 | 10.2% | -0.9 pp | +1.1 pp | |
| LTM Apr 2026 | 8.6% | +10.7 pp | +57.9 pp | |
| LTM Mar 2026 | 2.3% | +1.0 pp | +6.1 pp | |
| LTM Mar 2026 | 0.2% | +15.0 pp | +69.9 pp | |
| LTM Sep 2026 | -4.0% | +21.1 pp | +24.5 pp | |
| LTM Mar 2026 | -7.5% | -19.9 pp | +166.6 pp | |
| LTM Sep 2026 | -15.2% | +50.2 pp | +42.4 pp | |
| LTM Mar 2026 | -23.0% | -10.7 pp | -5.5 pp | |
| LTM Jan 2026 | -152.9% | -23.0 pp | — | |
| Peer median (excluding PHR) | -1.9% | +0.8 pp | +14.6 pp | |
Competitors are the stored peer set for PHR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Jan 2022 | FY2023 Jan 2023 | FY2024 Jan 2024 | FY2025 Jan 2025 | FY2026 Jan 2026 |
|---|---|---|---|---|---|
| Revenue | 213.23M | 280.91M | 356.3M | 419.81M | 480.59M |
| Cost of Revenue | 81.39M | 109.27M | 124.01M | 134.93M | 154.12M |
| Gross Profit | 131.85M | 171.64M | 232.29M | 284.88M | 326.47M |
| Gross Margin | 61.8% | 61.1% | 65.2% | 67.9% | 67.9% |
| Research & Development | 52.27M | 91.24M | 112.35M | 117.36M | 121.48M |
| Selling, General & Admin | 175.1M | 231.65M | 226.93M | 197.73M | 180.15M |
| Operating Expenses | 248.66M | 348.2M | 368.77M | 342.98M | 333.08M |
| Depreciation & Amortization | 24.52M | 28.77M | 30.54M | 27.89M | 31.45M |
| EBITDA | (92.3M) | (145.48M) | (102.95M) | (25.58M) | 29.47M |
| EBITDA Margin | -43.3% | -51.8% | -28.9% | -6.1% | 6.1% |
| Operating Income | (116.82M) | (176.55M) | (136.48M) | (58.1M) | (6.61M) |
| Operating Margin | -54.8% | -62.9% | -38.3% | -13.8% | -1.4% |
| Interest Income | 79K | 2.48M | 4.07M | 2.68M | 2.17M |
| Interest Expense | 1.16M | 1.41M | 1.85M | 2.35M | 6.95M |
| Other Income / Expenses | (1.16M) | 889K | 1.14M | 2.29M | (2.33M) |
| Income Before Tax | (117.98M) | (175.66M) | (135.34M) | (55.81M) | (8.94M) |
| Pre-Tax Margin | -55.3% | -62.5% | -38.0% | -13.3% | -1.9% |
| Income Tax Expense | 182K | 483K | 1.54M | 2.72M | (11.25M) |
| Net Income | (118.16M) | (176.15M) | (136.89M) | (58.53M) | 2.31M |
| Net Margin | -55.4% | -62.7% | -38.4% | -13.9% | 0.5% |
| EPS (Basic) | (2.37) | (3.36) | (2.51) | (1.02) | 0.04 |
| EPS (Diluted) | (2.37) | (3.36) | (2.51) | (1.02) | 0.04 |
| Weighted Avg Shares | 49.89M | 52.44M | 54.56M | 57.59M | 59.74M |
| Weighted Avg Shares (Diluted) | 49.89M | 52.44M | 54.56M | 57.59M | 61.49M |
Phreesia, Inc.
NYSE:PHR
Intrinsic Alpha fair value
Locked
Current Price
$12.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.